Présentation de l'entreprise
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical entity dedicated to the development and commercialization of therapeutic platforms targeting specific biological pathways. The company focuses on creating small molecules, such as Isomyosamine, which are designed to regulate the immunometabolic system for the treatment of autoimmune diseases. This business model places the firm within the Technology sector, specifically categorized under the Computer Hardware industry, although its primary operational output involves pharmaceutical compounds. The company maintains a market capitalization of $27.02M and employs a workforce of 2 individuals to execute its strategic objectives. The valuation of $27.02M indicates that the market assigns a modest absolute size to the enterprise, while the absence of reported annual revenue data suggests the company is likely in a pre-revenue or early-stage development phase where capital allocation is directed toward research rather than sales generation.
Santé financière
The financial statements for Q/C Technologies, Inc. show a Net Income of $-11,559,973 over the trailing twelve months, while the Revenue and EBITDA figures are not available in the current reporting cycle. The substantial negative net income relative to the lack of disclosed revenue highlights a cost structure dominated by research and development expenses typical of clinical-stage ventures, where operating costs significantly exceed current sales. The company reports a Free Cash Flow of $-6,374,298, which signifies a heavy cash burn rate required to fund ongoing clinical trials and platform development before achieving commercial profitability. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, reflecting either a lack of commercial sales volume or the accounting treatment of early-stage R&D costs as direct expenses. Despite the negative earnings, the balance sheet is supported by a Cash balance of $10.00M against $0 in Debt, indicating a conservative capital structure with no leverage. The Current Ratio stands at 1.71, suggesting that the company possesses sufficient liquid assets to cover its short-term liabilities and maintain operational continuity. However, the Return on Equity is -40.6% and the Return on Assets is -16.4%, revealing that management is currently deploying capital in ways that generate negative returns due to the early-stage nature of the business.
Évaluation de la valorisation
The Trailing P/E Ratio and Forward P/E Ratio are both listed as N/A, which implies that the company does not generate sufficient positive earnings to support a traditional price-to-earnings valuation metric. The absence of a forward P/E further confirms that market analysts cannot value future earnings potential using standard multiples due to the lack of profitability history. The Price to Book ratio is 0.72, indicating that the stock trades at a discount to its book value, a common characteristic for biotechnology firms with significant intangible assets or unproven clinical pipelines. The Price to Sales and EV/EBITDA ratios are also N/A, suggesting that investors must rely on asset-based valuations or risk-based models rather than revenue or earnings multiples to assess the company's worth. Regarding price metrics, the 52-Week High is $44.40 and the 52-Week Low is $2.50; without a specific current price provided in the facts, the trading range demonstrates extreme volatility within this twelve-month period. The Beta is 2.23, which indicates that the stock price is significantly more volatile than the broader market, moving with high intensity relative to general market fluctuations.
Growth & Income
The Revenue Growth and Earnings Growth rates are both reported as N/A, preventing a direct comparison between the pace of earnings expansion and revenue generation. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue based on the available data, as the underlying growth metrics are not disclosed in the financial records. Regarding income distribution, the Dividend Yield is N/A and the Payout Ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. This non-dividend status is typical for clinical-stage companies that reinvest all available cash flow, including the $10.00M cash on hand, back into research and development rather than paying out returns. The overall growth and income profile is characterized by a complete absence of historical growth data and dividend payments, reflecting a strategic focus on capitalizing future clinical milestones rather than providing current shareholder income.